Platelet-activating factor and bacteremia-induced pulmonary hypertension.

Area of Science:

• Pulmonary Medicine
• Sepsis Pathophysiology
• Vascular Biology

Background:

• Acute lung injury is a common complication of gram-negative sepsis, characterized by pulmonary hypertension and increased lung vascular permeability.
• Platelet-activating factor (PAF) is a key mediator in bacterial sepsis, influencing both pulmonary hypertension and edema.
• This study investigates the mechanism by which E. coli bacteremia induces pulmonary injury and the role of PAF.

Purpose of the Study:

• To elucidate the mechanism of PAF-induced pulmonary hypertension during E. coli bacteremia.
• To determine the role of endothelin-1 (ET) and nitric oxide (NO) in PAF-mediated pulmonary injury.
• To assess the contribution of neutrophil activation and sequestration to sepsis-induced lung injury.

Main Methods:

• Adult male Sprague-Dawley rats were subjected to E. coli bacteremia or sham sepsis.
• Hemodynamic parameters (PAP, BP, HR) and arterial blood gases were monitored.
• PAF receptor antagonist (WEB 2086) was administered to assess its inhibitory effects.
• Serum ET and nitric oxide metabolites (NOx) were measured, along with lung myeloperoxidase (MPO) activity and histology.

Main Results:

• E. coli bacteremia rapidly increased heart rate, pulmonary artery pressure, and respiratory rate within 20 minutes.
• Pretreatment with WEB 2086 completely prevented these hemodynamic changes.
• PAF-dependent mechanisms increased serum ET, lung MPO activity, and neutrophil sequestration.
• Increased NO production appeared to be independent of PAF.

Conclusions:

• E. coli bacteremia induces rapid pulmonary hypertension mediated by PAF, endothelin-1, and neutrophil activation.
• PAF also contributes to microvascular injury and lung leak, but hypoxemia develops more slowly.
• Hypoxic vasoconstriction is unlikely to be a significant contributor to early pulmonary hypertension in this model.